| Veronica W Butler, MD | |
|
120 N Ashwood Ave, Ventura, CA 93003-1810 | |
| (805) 658-5800 | |
| Not Available |
| Full Name | Veronica W Butler |
|---|---|
| Gender | Female |
| Speciality | Family Practice |
| Experience | 48 Years |
| Location | 120 N Ashwood Ave, Ventura, California |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1063472736 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Q00000X | Family Medicine | G86665 (California) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Community Memorial Hospital San Buenaventura | Ventura, CA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Community Memorial Health System | 9537155676 | 166 |
News Archive
A University of Adelaide researcher is leading a collaboration between Australia and Indonesia on the production of a universal flu vaccine. The frequent arising of new influenza strains represents the greatest challenge to health authorities as it renders currently available vaccines ineffective, says Dr Mohammed Alsharifi, the Head of the Vaccine Research Group at the School of Molecular and Biomedical Science, University of Adelaide.
Even though toys today are safer than ever before, parents shopping for Christmas presents for their children are being warned to be aware of the hidden hazards some toys present.
Researchers from Singapore-MIT Alliance for Research and Technology, MIT's research enterprise in Singapore, have developed a novel microcarrier for large-scale cell production and expansion that offers higher yield and cost-effectiveness compared to traditional methods, and reduces steps required in the cell retrieval process.
Men with advanced prostate cancer who take an experimental, high-dose vitamin D pill with chemotherapy live about eight months longer than those receiving chemotherapy and placebo, according to a new study.
Idera Pharmaceuticals today announced that 48% of patients with moderate-to-severe plaque psoriasis (12 of 25) treated with IMO-3100, a selective antagonist of Toll-like Receptors (TLRs) 7 and 9, demonstrated improvements in Psoriasis Area Severity Index (PASI) scores of 35% to 90% from baseline at the completion of a randomized, double-blind, placebo-controlled Phase 2a clinical trial of two dose levels of IMO-3100 administered for four weeks, with a four-week follow-up period.
› Verified 9 days ago
| Entity Name | Community Memorial Health System |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1215903018 PECOS PAC ID: 9537155676 Enrollment ID: O20040422001668 |
News Archive
A University of Adelaide researcher is leading a collaboration between Australia and Indonesia on the production of a universal flu vaccine. The frequent arising of new influenza strains represents the greatest challenge to health authorities as it renders currently available vaccines ineffective, says Dr Mohammed Alsharifi, the Head of the Vaccine Research Group at the School of Molecular and Biomedical Science, University of Adelaide.
Even though toys today are safer than ever before, parents shopping for Christmas presents for their children are being warned to be aware of the hidden hazards some toys present.
Researchers from Singapore-MIT Alliance for Research and Technology, MIT's research enterprise in Singapore, have developed a novel microcarrier for large-scale cell production and expansion that offers higher yield and cost-effectiveness compared to traditional methods, and reduces steps required in the cell retrieval process.
Men with advanced prostate cancer who take an experimental, high-dose vitamin D pill with chemotherapy live about eight months longer than those receiving chemotherapy and placebo, according to a new study.
Idera Pharmaceuticals today announced that 48% of patients with moderate-to-severe plaque psoriasis (12 of 25) treated with IMO-3100, a selective antagonist of Toll-like Receptors (TLRs) 7 and 9, demonstrated improvements in Psoriasis Area Severity Index (PASI) scores of 35% to 90% from baseline at the completion of a randomized, double-blind, placebo-controlled Phase 2a clinical trial of two dose levels of IMO-3100 administered for four weeks, with a four-week follow-up period.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Veronica W Butler, MD 5855 Olivas Park Dr, Ventura, CA 93003-7672 Ph: (805) 667-2801 | Veronica W Butler, MD 120 N Ashwood Ave, Ventura, CA 93003-1810 Ph: (805) 658-5800 |
News Archive
A University of Adelaide researcher is leading a collaboration between Australia and Indonesia on the production of a universal flu vaccine. The frequent arising of new influenza strains represents the greatest challenge to health authorities as it renders currently available vaccines ineffective, says Dr Mohammed Alsharifi, the Head of the Vaccine Research Group at the School of Molecular and Biomedical Science, University of Adelaide.
Even though toys today are safer than ever before, parents shopping for Christmas presents for their children are being warned to be aware of the hidden hazards some toys present.
Researchers from Singapore-MIT Alliance for Research and Technology, MIT's research enterprise in Singapore, have developed a novel microcarrier for large-scale cell production and expansion that offers higher yield and cost-effectiveness compared to traditional methods, and reduces steps required in the cell retrieval process.
Men with advanced prostate cancer who take an experimental, high-dose vitamin D pill with chemotherapy live about eight months longer than those receiving chemotherapy and placebo, according to a new study.
Idera Pharmaceuticals today announced that 48% of patients with moderate-to-severe plaque psoriasis (12 of 25) treated with IMO-3100, a selective antagonist of Toll-like Receptors (TLRs) 7 and 9, demonstrated improvements in Psoriasis Area Severity Index (PASI) scores of 35% to 90% from baseline at the completion of a randomized, double-blind, placebo-controlled Phase 2a clinical trial of two dose levels of IMO-3100 administered for four weeks, with a four-week follow-up period.
› Verified 9 days ago
Anna Mikhailovsky, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 3291 Loma Vista Rd, Ventura, CA 93003 Phone: 805-652-6228 | |
Dr. Michelle L Daucett, D.O. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 2721 E Main St, Ventura, CA 93003 Phone: 805-667-2841 Fax: 805-525-6778 | |
Dr. Fouzia Anwar Aftab, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 200 S Wells Rd, Suite 100 Clinicas Del Camino Real Inc, Ventura, CA 93004 Phone: 805-659-1740 Fax: 805-659-9959 | |
Dr. James Sands, MD Family Medicine Medicare: May Accept Medicare Assignments Practice Location: 2715 E Main St, Ventura, CA 93003 Phone: 805-643-2228 | |
Dr. Ramon Gomez, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 3291 Loma Vista Rd, Ventura, CA 93003 Phone: 805-652-6556 | |
Dr. Marisa Sportelli, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 3291 Loma Vista Rd, Ventura, CA 93003 Phone: 805-652-6556 | |
Dr. Geoffrey L Loman, M.D. Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 168 N Brent St, Ste 502, Ventura, CA 93003 Phone: 805-641-2000 Fax: 805-653-1644 |